Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in KoreaReal World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
- Other Titles
- Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
- Authors
- 임선민; 김상위; 조병철; 강진형; 안명주; 김동완; 김영철; 이진수; 이종석; 이승룡; 박건욱; 안호정; 조은경; 장태원; 김봉석; 김주항; 이성숙; 나임일; 유승수; 이기형
- Issue Date
- Oct-2020
- Publisher
- 대한암학회
- Keywords
- Non-small cell lung cancer; Anti–PD-1; Real-world data
- Citation
- Cancer Research and Treatment, v.52, no.4, pp.1112 - 1119
- Journal Title
- Cancer Research and Treatment
- Volume
- 52
- Number
- 4
- Start Page
- 1112
- End Page
- 1119
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78833
- DOI
- 10.4143/crt.2020.245
- ISSN
- 1598-2998
- Abstract
- Purpose The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.
Materials and Methods Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.
Results Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.
Conclusion This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, inclu-ding those with an older age.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78833)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.